On-Demand CME Videos
Matching the Right Patient with the Right Therapy: The Role of IL-17 Inhibitors for Psoriasis: Online CME Activity
This activity was recorded at the 2022 Fall Clinical Dermatology Conference on October 20, 2022.
Matching the Right Patient with the Right Therapy: The Role of IL-17 Inhibitors for Psoriasis
This activity is supported by an educational grant from UCB.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 15, 2022
November 15, 2024
At the completion of this activity, participants should be better able to:
Overview IL-17 inhibitors for the management of moderate-to-severe psoriasis
Describe how to prevent and manage side effects associated with IL-17 inhibitors
Discuss strategies to individualize care for patients with moderate-to-severe psoriasis
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
Bruce Strober, MD, PhD
Clinical Professor of Dermatology
Yale University School of Medicine
New Haven, CT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Consultant: AbbVie, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, EPI Health, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyxbio, vTv Therapeutics
Speakers’ Bureau or Honoraria: AbbVie, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme
Scientific Co-Director (consulting fee): CorEvitas (formerly Corrona) Psoriasis Registry
Investigator: Dermavant, AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Novartis
Editor-in-Chief (honorarium): Journal of Psoriasis and Psoriatic Arthritis
Ownership Interest: Connect Biopharma
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.